A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This phase 1 trial is testing a new type of stem cell transplant product called Orca-Q for patients with blood cancers who need a stem cell transplant from a donor. Orca-Q is a specially engineered version of donor stem cells designed to reduce serious complications, particularly graft-versus-host disease (where donor immune cells attack the patient's body) while still fighting the cancer. **You may be eligible if...** - You are between 12 and 78 years old (age limits vary by treatment arm and donor match) - You have been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype leukemia, or high-risk myelodysplastic syndrome (MDS) - Your disease is in remission or meets the specific disease criteria for the study arm - You have a suitable matched or partially matched donor **You may NOT be eligible if...** - You are outside the eligible age range for your specific treatment arm - Your leukemia is not in adequate remission - You have severe organ problems or active infections that make transplant unsafe - You do not have a suitable donor Talk to your doctor to see if this trial is right for you.